Wczytywanie spółki
Just reported
Q3 2026 results
From West Pharmaceutical Services's results release of 29 października 2026; its quarterly report has since been filed.
Revenue
Actual
874,5M USD
+8,7% y/y
+0,3% q/qGuided
827,5M USD
midpoint
Above guide+5,7%EPS, GAAP
Actual
3,02 USD
+57% y/y
+40% q/qGuided
—
No guide given
Operating income, GAAP
Actual
267,4M USD
+60% y/y
+49% q/qGuided
—
No guide given
Company outlook
Full year 2026
- Revenue3,41B USD – 3,42B USD+11% y/y Raised +1,6%
- EPS, adjusted9,38 USD – 9,48 USDRaised +5,4%
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes West Pharmaceutical Services is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Instruments and Supplies
Graded A or B and worth $2B or more: A first, then the largest.
ISRGIntuitive Surgical, Inc.153,8B USDA+
MDLNMedline Inc.51,9B USDA
ALCAlcon Inc.36,1B USDA
BLCOBausch & Lomb Corp7,5B USDA-
ATRCAtriCure, Inc.2,9B USDA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 paź 2026CBGraded C, now B
MCKMckesson Corporation4 lis 2026BAGraded B, now A
CVSCVS Health Corp4 lis 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 lis 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 paź 2026CAGraded C, now A
Pełne sprawozdania finansowe →
Zbudowane z własnych raportów spółki West Pharmaceutical Services Inc. składanych do amerykańskiej Komisji Papierów Wartościowych i Giełd (SEC). Liczby są takie, jak zaraportowano, a historia na akcję przeliczona na dzisiejszą bazę akcji. To opisuje firmę — nie jest poradą inwestycyjną ani rekomendacją kupna lub sprzedaży.
